Join Dan McCollum and EM clinical pharmacist RJ LaCoursiere as they discuss the use of buprenorphine for the treatment of Opioid Use Disorder. Who should be considered for treatment with Medication-Assisted Treatment (MAT)? Why should it be avoided if the patient isn't in acute withdrawal? What is a DEA X waiver and why should you look into getting waivered? How can we reduce stigma for these patients? Free training can be found at https://nhsc.hrsa.gov/loan-repayment/receive-medication-assisted-treatment-training . This podcast will be cross published with the Pharm So Hard podcast, so check them out for additional pharmacology pearls. A special thanks to student doctor Michael Stephens for editing this podcast.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related